Novartis have announced a 5% in net sales in 2018, bringing the total to $51.9bn.
Growth was primarily driven by Cosentyx (secukinumab), the human IgG1k monoclonal antibody for the treatment of psoriasis, ankylosing spondylitis and psoriatic arthritis.
Fourth quarter financial results indicated that Cosentyx delivered strong growth across the U.S. and EU with a 36% growth in the former and 32% growth in the rest of the world.
Net sales were also bolstered by an increasing demand for biosimilars which grew by 29% achieving a total of $390m.
Novartis is currently looking to launch ten new blockbuster medicines by 2020 including Zolgensma, a new gene therapy for the treatment muscle atrophy which was designated FDA fast-track last year.